Background The objective of the study was to study the utilization of specialist clinical services for haematological malignancy in a defined patient population. Patients with haematological malignancy are mostly aged over 65 years. Demographic projections for the United Kingdom suggest that the incidence of haematological malignancy will increase by 20 per cent in the next 20 years, mostly as a result of demographic change.
Introduction
There is little published work on the delivery of services for people with haematological malignancy. The majority of recent papers focus on biomedical issues such as treatment regimes, causes and aetiology. The few studies that have looked at service provision have centred on guidelines about general hospitalbased facilities and staffing, the management of clinical haematology services, the types of patient referred to a haematology department, or costings for acute haematological care. [1] [2] [3] [4] Considering that the majority of patients with haematological malignancy are aged over 65 years and have a chronic condition, this focus on service delivery within acute settings is surprising. The rising proportion of the ageing population in the United Kingdom, and hence the likely increase in the number of patients with haematological malignancy, led us to consider whether care for these patients could be provided within the setting of a community hospital, subject to the provision of appropriate resources and agreed clinical protocols. A literature review found a reference to one study on the contribution of community hospitals to the management of solid tumours, 5 but none to studies on the delivery of haematological care in these settings.
The configuration of the service organization in the Southampton and South West Health Authority district gave us the opportunity to assess the potential for management of haematological malignancies in a consultant-led community haematology service. As part of this assessment, we also estimated the likely increase in the demand for services for haematological malignancy brought about by changing demography.
How many patients with haematological malignancy need the facilities offered by a district general hospital?
Methods

Service settings
We undertook this study in two settings: first, Southampton General Hospital and the Royal South Hants Hospital, which together form part of Southampton University Hospitals Trust; second, Lymington Hospital, a community hospital in the New Forest. Both the community hospital in Lymington and Southampton University Hospitals Trust provide most basic interventions, with specialist interventions being available at Southampton.
Inclusion criteria
Patients were included if they were resident in any of six postcodes in the New Forest (Hampshire) area (estimated population approximately 181 000) and were attending a haematology out-patient clinic at either Lymington Hospital or the hospitals of the Southampton University Hospitals Trust during the period between 1 June and 9 September 1998, and who were diagnosed with one of the following haematological malignancies: chronic lymphocytic leukaemia, multiple myeloma, acute myeloid leukaemia, myelodysplastic syndrome, myeloproliferative disorders, chronic myeloid leukaemia, acute lymphocytic leukaemia, Hodgkin's disease, Non-Hodgkin's lymphoma.
Patient ascertainment and data collection
Patients were identified using lists prepared especially for the purpose by out-patient secretaries in the two settings. Lists were checked manually to avoid duplication by identifying patients attending on more than one occasion during the period studied. The hospital-based Patient Administration System was then used to identify the address of each patient and to allow his or her medical notes to be located. The following data were collected from medical notes for each patient on the final list:
(1) haematological diagnosis; (2) use of haematology services (visits to out-patient consultations, day case units and in-patient episodes, frequency and type of haematology interventions); (3) socio-demographic information (postcode of residence, age, gender); (4) co-morbidity (presence of cardiovascular disease, peripheral vascular disease, cerebrovascular accident).
Classification of interventions
Interventions were classified as simple, intermediate or complex according to the nature of nursing, medical and pharmacy resources needed to provide the procedures safely to an appropriate standard, in keeping with the guidelines produced by the British Committee for Standards in Haematology.
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Analyses
We compared the samples from the two sites in terms of patient baseline characteristics, the diagnosis and time since diagnosis of the haematological malignancy, domicile postcode and the use of haematological interventions.
Demographic changes in haematological malignancies
We calculated the likely rise in the numbers of new haematological malignancies in the United Kingdom by applying agespecific incidence rates obtained from published sources 6, 7 to future population projections for the year 2021, using 5-year age and sex bands.
8 Likely increases were calculated for the malignancies specified in the inclusion criteria.
Results
Case ascertainment
One hundred and ten out-patients were identified as living in the New Forest and fitting the above criteria. Eighty-two were using a clinic at Lymington Hospital and 27 a clinic at Southampton University Hospitals Trust. Eighty-seven of these 110 (79 per cent) were aged over 65 years, their median age being 74 years. There were no differences in the age, gender or co-morbidity of cases managed at the two centres (Table 1 ). There was little difference between centres in length of diagnosis with haematological malignancy ( Table 2 ). The majority of Lymington outpatient attendees were resident in the areas immediately surrounding Lymington, whereas the majority of the Southampton University Hospitals Trust attendees lived closer to Southampton.
Use of haematological interventions
Analysis of use of haematology services found that the sample of 110 out-patients had a total number of 355 visits (median two, inter-quartile range 2-3), at which 379 haematological interventions were performed (Table 3 ). Most interventions (356/379; 94 per cent) were basic in nature, comprising monitoring, oral chemotherapy, steroid therapy, blood transfusion and venesection, all of which were carried out in the framework of either out-patient consultation or a day case unit (Table 3) . Relatively few intermediate or complex interventions (23/379; 6 per cent) were required by our patient sample, of which in-patient episodes for haematological complications made up the largest component. All the intermediate and complex interventions were carried out in the specialist unit of the Southampton University Hospitals Trust. Not all the interventions described in Table 3 were utilized by our patient sample.
Demographic results
Approximately 156 new cases of haematological malignancy will currently present each year in a typical English Health Authority with a population of 500 000. Fifty-eight per cent of these will be people over 65 years. Assuming current age-and sex-specific incidence rates, this will have risen to 187 cases by the year 2021, a rise of 20 per cent. Of these 187, 61 per cent will be over 65 years. The high percentage of people aged over 65 seen in our study reflects local demography, the New Forest being a retirement centre for many people. 
Discussion
Most haematological malignancies are chronic disorders with a simple clinical management plan. Many cases are non-progressive but nevertheless require periodic clinical monitoring. Demographic projections show that the number of incident cases presenting each year will rise. Given a median survival of more than 3 years in many cases, an average district of half a million people, in 20 years time, could have from 60 to 80 extra prevalent cases requiring care at any one time.
In this study most interventions could be delivered in a framework of a consultant-led haematology service based in a community hospital. The majority of patients were over 65 years old, and the primary reason for attending a teaching hospital department appeared to be geographical proximity, although a few required the use of specialist facilities for intensive chemotherapy treatment and complications resulting from their haematological condition. Although we did not directly address the costs of providing haematological care in a community hospital, these are likely to be less than those of specialist hospital care. Care in a community setting has potentially greater acceptability for largely elderly patients and their carers, not least in reduced travel times, and could be linked to existing specialist facilities in a hub-and-spoke model.
The limitations of this study should be borne in mind. Patients were derived from a small population, giving room for statistical variation, and the study was conducted over a short space of time. Its retrospective nature provided a 'snapshot' of out-patient haematological services in a community hospital and its neighbouring district general hospital, and the information collected was limited to what was available from medical notes and limited specialist databases. We were primarily concerned with out-patient services, and so would have missed patients receiving care entirely as in-patients. We know that there were no incident cases of acute leukaemia in the study population over the period studied, however, reflecting the relative rarity of this presentation.
Specialist haemato-oncology services are clearly necessary, and this study does not seek to challenge that. A minority of patients will continue to need the intensive treatment facilities available in specialized centres, and it is likely that initial diagnosis and workup of patients with haematological malignancy will remain there. The majority of patients with haematological malignancies are elderly, with chronic conditions requiring largely out-patient care delivered as in this example by a consultant-led service based in a community hospital setting. Future studies are needed, however, to assess the cost-effectiveness and acceptability of delivering community-based haematological follow-up care, and to define appropriate clinical outcome measures, which can then be subject to simple audit (especially given the small numbers with any one specific malignancy). The impact on the primary care system of increasing the use of community hospitals or alternative community-based treatment facilities for haematology patients needs to be assessed. Improved clinical and epidemiological data are required for health care providers, for Strategic Health Authorities and for Primary Care Trusts, to assist in planning of resources to meet the needs of an increasing population of elderly patients and the consequent increase in the numbers of cases of haematological malignancy.
